Merck agreed to acquire Terns Pharmaceuticals in a $6.7 billion all-cash deal, paying $53 per share to bolster its oncology pipeline. The centerpiece is TERN-701, an oral BCR::ABL tyrosine kinase inhibitor in early-phase development for chronic myeloid leukemia, positioned to diversify Merck’s hematology exposure as revenue faces upcoming patent expiries.